Woodline Partners LP Purchases New Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Woodline Partners LP bought a new stake in Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 213,240 shares of the company's stock, valued at approximately $467,000. Woodline Partners LP owned 0.30% of Ventyx Biosciences at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. American Century Companies Inc. grew its holdings in shares of Ventyx Biosciences by 12.4% during the fourth quarter. American Century Companies Inc. now owns 67,329 shares of the company's stock valued at $147,000 after buying an additional 7,414 shares during the last quarter. Wells Fargo & Company MN lifted its position in Ventyx Biosciences by 23.3% in the 4th quarter. Wells Fargo & Company MN now owns 41,170 shares of the company's stock valued at $90,000 after acquiring an additional 7,768 shares in the last quarter. Barclays PLC boosted its stake in Ventyx Biosciences by 14.2% during the 4th quarter. Barclays PLC now owns 91,669 shares of the company's stock valued at $200,000 after purchasing an additional 11,374 shares during the last quarter. Catalina Capital Group LLC bought a new stake in Ventyx Biosciences during the 4th quarter worth approximately $25,000. Finally, MetLife Investment Management LLC raised its stake in shares of Ventyx Biosciences by 76.0% in the fourth quarter. MetLife Investment Management LLC now owns 26,731 shares of the company's stock worth $59,000 after purchasing an additional 11,543 shares during the last quarter. 97.88% of the stock is owned by institutional investors.

Ventyx Biosciences Trading Down 7.5%

Shares of NASDAQ:VTYX traded down $0.14 during mid-day trading on Friday, hitting $1.68. 1,270,791 shares of the company traded hands, compared to its average volume of 1,337,066. The stock has a 50-day moving average price of $1.25 and a two-hundred day moving average price of $1.73. Ventyx Biosciences, Inc. has a 12-month low of $0.78 and a 12-month high of $5.66. The stock has a market cap of $119.19 million, a P/E ratio of -0.71 and a beta of 0.73.

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.48) by $0.09. As a group, analysts expect that Ventyx Biosciences, Inc. will post -2.09 earnings per share for the current year.

Ventyx Biosciences Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.